This meta-analysis of the pooled data provided evidence that the high/positive expression of HER4 was significantly associated with a better prognosis in terms of RFS regardless of the molecular subtype of breast cancer and implied the importance of HER4 in predicting the OS of patients with non-TNBC. This evidence concerns the gene ERBB4 and breast carcinoma.